EULAR RAID.7工具评估类风湿关节炎个体疾病影响域的有效性与可靠性:671例横断面研究
该研究基于RAID横断面数据集(563例)和Rainbow试验数据集(108例),共分析671例确诊类风湿关节炎患者,评估RAID问卷7个数值评定量表(NRS)各自的心理测量学特性。各NRS与相应外部参照工具呈中度至强相关(r=0.62-0.81),重测信度ICC为0.64(疼痛)至0.83(睡眠障碍),标准化反应均值为0.93(睡眠障碍)至1.34(疼痛)。结论认为RAID.7各条目单独使用有效、可行、可靠且对变化敏感。
要点
- RAID.7各NRS与外部参照工具相关r=0.62-0.81,结构效度良好。
- 重测信度ICC范围0.64(疼痛)至0.83(睡眠障碍)。
- 标准化反应均值0.93(睡眠障碍)至1.34(疼痛),对变化敏感。
核心结论
- RAID.7的7个NRS单独使用有效、可行、可靠且对变化敏感,可在最小问卷负担下改善疾病影响的评估与治疗。
研究设计与样本
- 对RAID横断面研究和Rainbow研究(依那西普开放标签12周试验)数据进行事后分析,共纳入671例确诊类风湿关节炎患者(RAID 563例,Rainbow 108例)。
- 在RAID数据集中通过Spearman相关评估各NRS与相应外部参照工具的结构效度。
- 在Rainbow数据集中通过筛查访视与基线访视间的组内相关系数评估信度,通过基线与12周间的标准化反应均值评估反应性。
主要发现
- 各NRS与相应外部参照工具呈中度至强相关(r=0.62-0.81)。
- 重测信度ICC范围为0.64(0.51-0.74)(疼痛)至0.83(0.76-0.88)(睡眠障碍)。
- 标准化反应均值范围为0.93(0.73-1.13)(睡眠障碍)至1.34(1.01-1.64)(疼痛)。
临床怎么用
- 临床可单独使用RAID.7各NRS评估类风湿关节炎患者疼痛、功能、疲劳、睡眠、情绪、躯体健康及应对等个体疾病影响域,以指导针对性干预。
局限性
- 研究为事后分析,信度与反应性评估基于Rainbow试验中依那西普治疗患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The rheumatoid arthritis impact of disease (RAID) questionnaire comprises seven patient-important domains of disease impact (pain, function, fatigue, sleep disturbance, emotional well-being, physical well-being, coping). RAID was validated as a pooled-weighted score. Its seven individual items separately could provide a valuable tool in clinical practice to guide interventions targeting the patient's experience of the disease. The aim was to separately assess the psychometric properties of each of the seven numeric rating scale (NRS) of the RAID (RAID.7). MATERIAL AND METHODS: Post hoc analyses of data from the cross-sectional RAID study and from the Rainbow study, an open-label 12-week trial of etanercept in patients with RA. Construct validity of each NRS was assessed cross-sectionally in the RAID data set by Spearman's correlation with the respective external instrument of reference. Using the rainbow data set, we assessed reliability through intraclass correlation coefficient between the screening and the baseline visits and responsiveness (sensitivity to change) by standardised response mean between baseline and 12 weeks. RESULTS: A total of 671 patients with RA with features of established disease were analysed, 563 and 108 from RAID and Rainbow, respectively. The NRS correlated moderately to strongly with the respective external instrument of reference (r=0.62-0.81). Reliability ranged from 0.64 (0.51-0.74) (pain) to 0.83 (0.76-0.88) (sleep disturbance) and responsiveness from 0.93 (0.73-1.13) (sleep disturbance) to 1.34 (1.01-1.64) (pain). CONCLUSION: The separate use of the individual NRS of RAID (RAID.7) is valid, feasible, reliable and sensitive to change, representing an opportunity to improve the assessment and treatment of disease impact with minimal questionnaire burden. TRIAL REGISTRATION NUMBER: NCT00768053.
引用
- Duarte C, Santos EJF, Ferreira RJO, et al. Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients. RMD Open. 2021. PMID: 33547229. doi:10.1136/rmdopen-2020-001539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。